Lawrence Karsh, MD, FACS

Lawrence Karsh, MD, FACS

The Urology Center of Colorado

Denver, CO

Dr. Karsh has practiced Urology in Denver since 1984 and was board Certified in 1986, completing the most recent recertification in 2013. He graduated from the Chicago Medical School and completed his General Surgical training at The University of Colorado Health Sciences Center under Dr. Thomas Starzl. He completed his Urology residency at Brigham and Women's Hospital/Harvard Medical School under Dr. Ruben Gittes.[su_spacer] Dr. Karsh is a co-founder of The Urology Center of Colorado where he serves as an attending Urologist and Director of Research. He is a principal investigator with an experience of more than 200 clinical trials. He is a Certified Principal Investigator, certified by the Association of Clinical Research Professionals (ACRP.) Dr. Karsh has authored a number of peer-reviewed publications and serves on the editorial boards for "Urologists in Cancer Care" and "Bladder Cancer." He is an active member of the AUA, SUO,ASCO, as well as SWOG. He serves on the bladder cancer subcommittee for the SUO Clinical Trials Consortium.[su_spacer] Dr. Karsh is also a member of the Denver Academy of Surgeons. Dr. Karsh serves as an advisor and consultant to the pharmaceutical industry, participating in drug development and research protocols. He educates physicians across the country about newly approved therapies.

Articles by Lawrence Karsh, MD, FACS

Point Counterpoint in ADT—Agonists versus Antagonists

Lawrence Karsh, MD, FACS, argues that agonists are effective, sustainable androgen deprivation therapies (ADT) for treating prostate cancer, and claims that agonists present a high cardiovascular (CV) risk could be due to selection bias in trials. Conversely, Thomas Keane, MD, argues that patients treated with antagonists have lower CV risk and are more responsive to ADT than those treated with agonists.

Read More
  • 1
  • 2

Join the GRU Community

- Why Join? -